TCM
GTHX

Towercrest Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Towercrest Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,500
Closed -$235K – 97
2021
Q3 		$235K Buy
+17,500
New +$285K 0.04% 90

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Towercrest Capital Management's GTHX Position: Q4 2021 in Review

Towercrest Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2021, closing a stake of 17,500 shares — an estimated $235K sold.

Towercrest Capital Management first reported a position in GTHX in Q3 2021 and held it in 1 quarter. The position peaked at $235K in Q3 2021. 108 funds tracked by Wall St. Rank hold GTHX as of Q4 2021.

  • Towercrest Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Towercrest Capital Management sold 17,500 G1 Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $235K.
  • Towercrest Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Towercrest Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $235K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Towercrest Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.